BSE (bovine spongiform encephalopathy) is a progressive neurological disorder of cattle, and has been called “mad cow disease.” Its symptoms are similar to “scrapie,” a brain disease that occurs in sheep.

Cattle affected by BSE experience progressive degeneration of the nervous system. Affected animals may display changes in temperament, such as nervousness or aggression, abnormal posture, incoordination and difficulty in rising, decreased milk production, or loss of body weight despite continued appetite. Affected cattle die. There is neither any treatment nor a vaccine to prevent the disease.

The incubation period (the time from when an animal becomes infected until it first shows disease signs) is from 2 to 8 years. Following the onset of clinical signs, the animal’s condition deteriorates until it either dies or is destroyed. This process usually takes from 2 weeks to 6 months. Most cases in Great Britain have occurred in dairy cows between 3 and 6 years of age.

Learn more about Bovine Spongiform Encephalopahty.

Yes. The human diseases are very rare and occur sporadically worldwide at a rate of about one case per one million people.

BSE belongs to a group of progressive degenerative neurological disease known as transmissible spongiform encephalopathies (TSEs). TSE diseases are always fatal.

The TSE diseases include:

• Scrapie, which affects sheep and goats
• Transmissible mink encephalopathy
• Feline (cat) spongiform encephalopathy
• Chronic wasting disease of deer and elk

There are six TSE diseased that affect people:

• Kura
• Classical Creutzfeldt Jakob disease (CJD)
• Variant Creutzfeldt-Jakob disease (vCJD)
• Gerstmmann-Straussler-Scheinker syndrome
• Fatal familial insomnia
• Sporadic fatal insomnia

CJD is a slow degenerative human disease of the central nervous system. It is classified as a transmissible spongiform encephalopathy because of the characteristic spongy degeneration of the brain that occurs as the disease progresses.

CJD occurs sporadically worldwide at a rate of 1 case per 1 million people per year.

Learn more about Creutzfeldt-Jakob disease.

Variant Creutzfeldt- Jakob disease (vCJD) is another rare and fatal human neurological disease that falls into the category of transmissible spongiform encephalopathies (TSEs).

Like Creutzfeldt- Jakob disease (CJD), vCJD causes a spongy degeneration of the brain. vCJD is a new disease which was first described in March 1996.

Some cases of variant Creutzfeldt- Jakob disease have been attributed to, among other possibilities, eating beef products from cattle infected with the agent of BSE.

However, no evidence exist that cases of vCJD are related to the use of vaccines, and no cases of vCJD have ever been reported in United States.

Vaccines contain either killed or weakened forms of disease-causing bacteria or viruses, or components of these that stimulate a response by the body’s immune system, which then protects against the development of disease.

Although synthetic media have been developed for growth of many medically important microorganisms, some still require additional nutrients which are provided by animal-derived products such as serum and blood. No bovine material has ever been used as an active ingredient of any vaccine.

In the late 19th century, microbiologist began to grow bacteria in the laboratory. The early bacteriologist tried to mimic as closely as possible the infected person’s tissues by using sugars, salts, and various meat extracts to make “growth media.”

These kinds of conditions were quite successful in growing bacteria and then viruses in the lab, because these media supplied the many necessary nutrients.

Animal-derived products used in vaccine manufacture can include:

• Amino acids
• Glycerol
• Detergents
• Gelatin
• Enzymes
• Blood
• Cow milk is a source of amino acids, and sugars such as galactose.
• Cow tallow derivatives used in vaccine manufacture include glycerol.
• Gelatin and some amino acids come from cow bones.
• Cow skeletal muscle is used to prepare certain complex media.
• Many difficult to grow microorganisms required the addition of serum from blood to the growth media.

Scientists have found that different bovine tissues contain different amounts of the BSE agent. It is generally believed that the highest amounts of infectivity are found in the brain and spinal cords from animals in the final stages of clinical disease.

Some tissues such as skeletal muscle and milk have never been shown to have any infectivity. However, the slaughtering and butchering methods used to obtain tissues and prepare materials can affect the amount of infectivity that may be present.

Also the production processes used to prepare bovine-derived materials (such as heat sterilization and chemical treatment) may reduce or remove infectivity.

Initially, the USDA list included only countries and other regions in which BSE was known to exist, such as the United Kingdom, France, Switzerland, and the Republic of Ireland.

In 1998, the USDA expanded the list to include countries and other regions in which BSE had not been documented but in which import requirements were less restrictive than requirements that would be acceptable for import into the United States or in which there was inadequate BSE surveillance.

Thus, all European countries, even those that have had no reported cases of BSE, are currently on the USDA list, which is published in the Code of Federal Regulations, title 9, part 94 (9C.F.R., part 94).

Both the FDA and its joint advisory committee concluded that the risk for vCJD posed by vaccines is theoretical and remote. Studies of the BSE agent have shown that infectivity depends on nature of material used, how much is used and the route of administration.

Other factors, such as the country of origin of the cattle used to supply the manufacturing material, also have to be factored into any risk estimate. Both the European Community and the US Pharmaceutical industry have presented risk assessment calculations which attempt to account for all these factors.

In 1999, the Council on Scientific Affairs (CSA) of American Medical Association considered the risk of BSE to public health and determined that the current risk of transmission of BSE in the US is minimal, concluding that adequate guidelines exist to prevent high risk bovine materials from contaminating products intended for human use.

The report from the CSA did not address the possibility that regulated industry might not follow all of the recommendations made by the FDA. However, both FDA and the joint advisory committee meeting have considered the risks posed by bovine material in vaccines and concluded that any risk is remote and theoretical.

There is no evidence to date that vaccines have contributed to the cases of vCJD seen in Europe. Nor is there evidence that any vaccines harbor the BSE agent.

Vaccines are given a very limited number of times via the intramuscular, subcutaneous or oral route. Even in experimental studies, these routes of administration are less effective at spreading the agent than the intracerebral route usually used to assess infectivity in animal studies.

The amount of infectivity present and the efficiency with the BSE agent passes from cow material to humans will also affect the likelihood of infection.

Scientists, regulatory authorities in Europe and the pharmaceutical industry of the U.S. have considered the risk of BSE in pharmaceutical products.

In estimating these risks it is necessary to consider the:

• Country of origin of any bovine material
• Type of bovine tissue used
• Steps used to process the bovine tissue
• Amount of bovine derived material used
• Stage of vaccine manufacture at which the bovine material is used

Using previously published methods for calculating theoretical risk of cased of vCJD from pharmaceutical products, FDA has calculated a conservative estimation of the risk of a vaccine causing a case of vCJD. These estimates were presented in public session at the joint advisory committee meeting on July 27, 2000.

FDA believes these estimations are a realistic worst case scenario and that the real risk any US licensed vaccine could cause vCJD is even lower than the estimates presented (link to risk assessments and transcripts).

FDA has taken a number of measures to minimize any chance that the BSE could be introduced into biologic products during manufacture.

Most recently, FDA has directed manufactures not to use products from animals born, living, or slaughtered in countries where BSE has occurred, or countries where there is a high or unknown risk of BSE.

In this recent action, the FDA has requested that vaccine manufactures replace bovine-derived materials obtained from countries on the USDA list with materials obtained from countries not on the USDA list.

This recommendation, which is consistent with existing FDA guidance first issued in 1993 on the sourcing of bovine-derived materials, is intended to reduce even the remote risk for vCJD from vaccines.

No. The Public Health Service (PHS) recommends that all persons continue to be vaccinated according to current schedules. No evidence exists that cases of vCJD are related to the use of vaccines, and no cases of vCJD have ever been reported in the U.S.

In addition, there is no evidence to date that vaccines have contributed to the cases of vCJD seen in Europe. Nor is there evidence that any vaccines harbor the BSE agent.

As a result, PHS has no preference for using one licensed vaccine product over another based on the source of bovine-derived materials used in vaccine production.

The FDA is taking this action as a precautionary measure. This action is intended to reduce even the remote risk for vCJD from vaccines.

All of the affected manufactures have agreed to implement these changes or have already done so. FDA anticipates that most of these changes will be completed in 2001.

No. The Public Health Service (PHS) recommends that all persons continue to be vaccinated according to current schedules. No evidence exist that cases of vCJD are related to the use of vaccines, and no cases of vCJD have ever been reported in the U.S.

In addition, there is no evidence that any vaccines harbor the BSE agent. As a result, PHS has no preference for using one licensed vaccine product over another based on the source of bovine-derived materials used in vaccine production.

The FDA has looked at the benefit of vaccines and the risk of vCJD from vaccine use. Vaccines have a proven benefit in reducing the incidence of serious, often life-threatening diseases.

Conversely, the Public Health Service, FDA and the members of FDA’s advisory committees on TSE and Vaccines and Related Products (VRBPAC) believe the risk that anyone will get vCJD from a vaccine is remote and theoretical.

Failure to obtain recommended vaccinations with licensed vaccines puts a person at risk for serious disease. Without routine vaccination, the incidence of disease would increase. This was seen in Sweden, Japan and the UK when the number of children vaccinated against pertussis decreased due to concerns about vaccine adverse events associated with the whole-cell DTP vaccine.

In addition, removal of safe and effective licensed vaccines from the market could cause insufficient supply and potentially increase the number of unvaccinated or under vaccinated individuals at risk from preventable diseases.

Additional information about BSE or vaccines manufactured with bovine-derived materials from countries on the U.S. Department of Agriculture’s list can be obtained from the FDA’s web site, www.FDA.gov, or from the Center of Biologics Evaluation and Research at (800) 835-4709.